TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19549433
Drug: Somatropin inhalation
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Somatropin inhalation powder (SIP)
Study: 11879237
Drug: Molecular Adsorbents
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular Adsorbents Recycling System (MARS) treatment
Study: 9880443
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (L‐GG)
Study: 7721639
Drug: Pretreatment quality
Normalized name: Quality Choice Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment quality control review of radiation therapy fields
Study: 23656594
Drug: Milk with
Normalized name: BETTERMILK with Glytactin 10PE Powder for Suspension (Orange Creme)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk with L. paracasei SD1
Study: 19172517
Drug: Pitavastatin 2
Normalized name: PITAVASTATIN 2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2 mg once daily (group A)
Study: 19172517
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 1800 mg daily (group B)
Study: 19172517
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of pitavastatin and EPA (group C)
Study: 16848361
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy after radical prostatectomy
Study: 11069375
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy alone
Study: 16848361
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal therapy (combined with prostatectomy and radiotherapy)
Study: 14693305
Drug: Stevioside (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stevioside (500 mg, 3 times daily for 2 years)
Study: 10978399
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (60 mg/day)
Study: 1345022
Drug: Apulein cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apulein cream
Study: 29607554
Drug: Hydrocortisone ointment
Normalized name: Hydrocortisone Ointment
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone ointment
Study: 25690268
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment and diabetes education
Study: 25690268
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (at screening)
Study: 22116471
Drug: Cognitive treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive treatment, exposure treatment, or their combination with fluvoxamine
Study: 20518948
Drug: ERN/LRPT (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN/LRPT (1 g) plus statin, advanced to ERN/LRPT (2 g) after 4 weeks
Study: 12397697
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II type 1 receptor antagonist losartan
Study: 12397697
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme (ACE) inhibitor enalapril
Study: 12397697
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist amlodipine
Study: 10457578
Drug: Interferential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential therapy
Study: 7015692
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vincristine, nitrosomethylurea, and dactinomycin
Study: 7015692
Drug: DTIC (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTIC (150 mg/m2 iv days 1, 2, 3, 4, 5)
Study: 21247622
Drug: Synchrovine® (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synchrovine® (two doses of PGF(2α), 7 d apart)
Study: 15643648
Drug: Transdiagnostic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic treatment for anxiety
Study: 3391736
Drug: PPA 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA 37.5 mg (immediate release formulation)
Study: 31294771
Drug: Ranibizumab, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab, 0.5 mg, every 4 weeks
Study: 31294771
Drug: Aflibercept, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept, 0.5 mg, every 4 weeks
Study: 28751662
Drug: L p
Normalized name: Midol PM
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L p -Adaptation method
Study: 29111115
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg/day)
Study: 21050274
Drug: 0.50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg/kg YS
Study: 15496223
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Donepezil + Risperidone and Donepezil only)
Study: 9736892
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy intervention (twice‐weekly for 18 weeks)
Study: 3276492
Drug: Thymopentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (50 mg, intravenous injections, three times weekly)
Study: 26166526
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education group (received oral health education for 3 years)
Study: 22069382
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low-frequency right prefrontal followed by low-frequency left temporal rTMS
Study: 26792348
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline injection)
Study: 9598455
Drug: WR 238605
Approvals — FDA: no, EMA: no, PMDA: no
Description: WR 238605 (doses ranging from 4 to 600 mg)
Study: 3280829
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 or 50 mg daily)
Study: 3280829
Drug: Magnesium hydroxide
Normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium hydroxide (650 or 1300 mg daily)
Study: 29024892
Drug: Life Review
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life Review Therapy (4-week duration)
Study: 24201679
Drug: Weekly supervised
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supervised pelvic floor muscle training class and daily home exercise for 16 weeks.
Study: 7649712
Drug: Glycosaminoglycan polysulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosaminoglycan polysulfate (GAGPS) injections
Study: 2745867
Drug: Computer-aided pharmacokinetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-aided pharmacokinetic method of aminoglycoside dose prediction
Study: 27107097
Drug: Esomeprazole-based regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole-based regimen (20 mg)
Study: 27107097
Drug: Omeprazole-based regimen
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-based regimen (20 mg)
Study: 14633079
Drug: Terazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1 mg, twice-a-day) for 12 weeks
Study: 10963819
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosing of glibenclamide
Study: 10963819
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily dosing of glibenclamide
Study: 8909669
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (0.15 mg/kg)
Study: 30088695
Drug: Concurrent smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent smoking status verified using expired carbon monoxide
Study: 23063221
Drug: Combined NAI
Normalized name: Shan Nai
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined NAI and PUI after CaOH(2) medication
Study: 10617169
Drug: Paroxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (40 mg)
Study: 24653510
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/d)
Study: 16125367
Drug: TAU (Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (Treatment as Usual) - standard treatment without special training
Study: 7857100
Drug: UFT with
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT with leucovorin tablet (400 mg/day of UFT with 20 mg/day of leucovorin)
Study: 7857100
Drug: UFT alone
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT alone (400 mg/day of UFT)
Study: 1678445
Drug: Ampicillin (25‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (25‐30 mg/kg body weight three times daily for 5 days) plus supportive care
Study: 31077610
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) + Parent Psychoeducation (TEPSI)
Study: 29423579
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral rectus sheath block (US-BRSB) with 30 ml of 0.25% ropivacaine
Study: 16815141
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 500 mcg, twice daily for 2 weeks
Study: 9212476
Drug: Non-priming group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-priming group (n = 20) received mivacurium 0.25 mg/kg
Study: 8402628
Drug: Vorozole racemate
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorozole racemate 1 mg
Study: 8402628
Drug: Vorozole racemate
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorozole racemate 5 mg
Study: 24839862
Drug: Sucrose drink
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose drink (100 g in 250 ml)
Study: 24839862
Drug: Placebo (artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (artificial sweeteners in 250 ml)
Study: 18665934
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus yogurt (yogurt group, n = 168)
Study: 18665934
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy only (control group, n = 179)
Study: 11276273
Drug: Nabumetone (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1,000 to 2,000 mg/d)
Study: 11276273
Drug: Diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (100 to 150 mg/d)
Study: 7696941
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg aspirin daily
Study: 22850220
Drug: Infusions prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions prepared by pharmacy and industry
Study: 15589470
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and steroids
Study: 15589470
Drug: Ciclosporin A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin A, steroids, azathioprine, and ATG
Study: 12405554
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) of 5 mg of LY 156735
Study: 8590851
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of rhG-CSF post chemotherapy with ProMACE/CytaBOM regimen
Study: 8590851
Drug: Previous study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous study without rhG-CSF administration
Study: 1674632
Drug: Carvedilol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (5 mg)
Study: 2975095
Drug: Nifedipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (2 mg)
Study: 2609718
Drug: Nifedipine +
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine + Propranolol (2 mg + 5 mg)
Study: 991149
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of agents including DTIC
Study: 23035175
Drug: ACE527 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE527 vaccine
Study: 17244104
Drug: Morphine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (administered intravenously)
Study: 18313505
Drug: Other agents
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other agents
Study: 23387822
Drug: Intravenous t‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous t‐PA
Study: 3315193
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide and lorazepam (M+L)
Study: 3315193
Drug: Prochlorperazine and
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prochlorperazine and lorazepam (P+L)
Study: 28025924
Drug: Increased number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased number of chronic medications
Study: 18326619
Drug: Novel galactooligosaccharide
Normalized name: fructooligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel galactooligosaccharide (0, 3.6, or 7 g/d)
Study: 18326619
Drug: Novel galactooligosaccharide
Normalized name: fructooligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel galactooligosaccharide (7 g/d)
Study: 7493372
Drug: IFN-alpha treatment
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha treatment
Study: 3320366
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg twice daily
Study: 28475703
Drug: Cibinetide 1
Normalized name: Cibinetide
DrugBank: Cibinetide (DB13006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibinetide 1 mg/day
Study: 28475703
Drug: Cibinetide 4
Normalized name: Cibinetide
DrugBank: Cibinetide (DB13006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibinetide 4 mg/day
Study: 28475703
Drug: Cibinetide 8
Normalized name: Cibinetide
DrugBank: Cibinetide (DB13006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cibinetide 8 mg/day
Study: 25512031
Drug: Bupivacaine (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.25% solution with adrenaline) alone
Study: 22585373
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate oral disintegrating tablets (specific formulation details: magnesium stearate as lubricant, hydrophobic Aerosil R972 as glidant, low urea content, mannitol/microcrystalline cellulose ratio 2:1, and 9% Plasdone XL100 as superdisintegrant)
Study: 11844850
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with S. aureus type 5 and 8 capsular polysaccharides conjugated to nontoxic recombinant Pseudomonas aeruginosa exotoxin A
Study: 26781281
Drug: Taurine supplementation
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine supplementation (1.6 g per day)
Study: 18715950
Drug: Motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motexafin gadolinium (MGd) at doses of 1.7 to 9.2 mg/kg daily prior to radiation therapy for 6 weeks
Study: 18715950
Drug: Motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motexafin gadolinium (MGd) administered as a 5-min intravenous bolus 2-5 h prior to standard radiation therapy
Study: 18715950
Drug: Involved field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved field radiation therapy administered to 54 Gy in 30 once-daily fractions
Study: 14975200
Drug: HRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT plus fluoxetine
Study: 11700394
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of rhAPC (12, 18, 24, or 30 microg/kg/hr) for 48 or 96 hrs
Study: 22901887
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg three times a week for 6 months
Study: 8023546
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A vaccine (Havrix) stored at 37 degrees C for 1 week
Study: 3531295
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg twice daily
Study: 30057745
Drug: GM604 (compassionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM604 (compassionate treatment)
Study: 26531865
Drug: Suboptimal SCIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal SCIT (30,000 standardized quality units) plus placebo antibody
Study: 26531865
Drug: Double placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double placebo (placebo SCIT and placebo antibody)
Study: 23022391
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Ze 440
Study: 23022391
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Ze 440
Study: 23022391
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg Ze 440
Study: 15302290
Drug: Optimal surgical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal surgical treatment plus adhesion barrier (SprayGel)
Study: 15302290
Drug: Optimal surgical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal surgical treatment alone
Study: 8580980
Drug: Moxisylyte 10
Normalized name: moxisylyte
DrugBank: Moxisylyte (DB09205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxisylyte 10 mg
Study: 8580980
Drug: Moxisylyte 20
Normalized name: moxisylyte
DrugBank: Moxisylyte (DB09205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxisylyte 20 mg
Study: 8580980
Drug: Moxisylyte 30
Normalized name: moxisylyte 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxisylyte 30 mg
Study: 772817
Drug: Azathioprine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (50 to 175 mg/day)
Study: 14969665
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC)
Study: 12114886
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg/day
Study: 15488162
Drug: Washing of
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washing of the CVP using normal saline solution before each closure and every 6 hours
Study: 15488162
Drug: Closure of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closure of the CVP using an obturator after the suspension of the infused therapy
Study: 11201509
Drug: Estrogen (Premarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (Premarin 0.625 mg) and medroxyprogesterone acetate (Provera 5 mg)
Study: 21073640
Drug: Make A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Make A Difference about Art programme (art therapy intervention)
Study: 11905780
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy for advanced laryngeal cancer
Study: 11905780
Drug: Chemotherapy given
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy given concomitantly with radiotherapy
Study: 9737645
Drug: Cerivastatin 0.025-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.025-0.4 mg/day
Study: 9737644
Drug: Cerivastatin (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (higher doses)
Study: 9737644
Drug: Cerivastatin (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (long-term administration)
Study: 7536025
Drug: G-CSF (Filgrastim)
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (Filgrastim) 300 microgram s.c. daily
Study: 2665058
Drug: Insulin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (7.5 U fast-acting insulin/kg b.w. as a bolus followed by continuous infusion of 15 U/kg b.w. for 1 hour)
Study: 2665058
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no insulin treatment)
Study: 29966016
Drug: Non-administration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-administration group
Study: 16984757
Drug: Stimulated cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulated cycles with recombinant FSH and human gonadotrophin hormone injection
Study: 9493920
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy with occasional hypnotics
Study: 9493920
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy without hypnotics
Study: 8348061
Drug: Isotretinoin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (10 mg/day)
Study: 25730596
Drug: EX +
Normalized name: Freeflex + Transfer Adapter
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX + SUPP (combined home‐based exercise and calcium and vitamin D supplements)
Study: 25730596
Drug: SUPP (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUPP (calcium and vitamin D supplements alone)